Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of RO7790121 for induction and maintenance treatment in moderate to severe active ulcerative colitis
CTR20244106Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of afimkibart in autoimmune colitis, sponsored by Roche. Started Mar 2025; status: active.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20244106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244106.